Literature DB >> 12436434

Nitric oxide pathways in human bladder carcinoma. The distribution of nitric oxide synthases, soluble guanylyl cyclase, cyclic guanosine monophosphate, and nitrotyrosine.

Amgad Ehsan1, Frank Sommer, Annette Schmidt, Theodor Klotz, Jolanta Koslowski, Sandra Niggemann, Georg Jacobs, Udo Engelmann, Klaus Addicks, Wilhelm Bloch.   

Abstract

BACKGROUND: Nitric oxide (NO) is produced by a group of synthase enzymes (NOS). By means of different pathways, NO exerts several functions in benign and malignant human bladder tissues. The current paper describes the NO/guanylate cyclase (sGC)/cyclic guanosine monophosphate (cGMP) and the NO/oxidative pathways in human bladder tissues.
METHODS: Bladder carcinoma tissues were collected from 18 patients by transurethral resection procedures. Normal benign vesical tissue specimens from a further eight patients with benign diseases served as controls. Immunohistochemistry was conducted for localization of sGC, cGMP, and nitrotyrosine in benign and malignant vesical tissues, evaluating two-three tissue sections per patient.
RESULTS: Positive immunolabeling for sGC and cGMP was detected in vascular endothelial cells of normal and malignant vesical tissues. Those signals were most intense in bladder carcinoma tissues. Immunolabeling for sGC and cGMP was also detected in normal urothelial cells. In bladder carcinoma cells, a heterogeneous immunolabeling for sGC and cGMP was seen, with a wide spectrum of signal intensity. Positive immunostaining for sGC and cGMP was also observed in stromal round cells in benign and malignant bladder tissues. Immunolabeling for nitrotyrosine was mainly observed in endothelial cells, with a much stronger immunolabeling in bladder carcinoma tissues compared to normal benign controls. A weak immunolabeling for nitrotyrosine was also observed in bladder carcinoma cells. Normal urothelial cells did not show such nitrotyrosine expression.
CONCLUSIONS: The current report provides evidences that NO play several roles through different pathways in benign and malignant vesical tissues. The influences generated by NO molecules can be divided into cGMP-mediated effects (those resulting from the NO/sGC/cGMP pathway) and non-cGMP-mediated effects (those resulting from the NO/oxidative pathway). Increased angiogenesis is a cGMP-mediated effect, while nitrotyrosine production is a non cGMP-mediated oxidative effect. Such an NO/oxidative pathway is observed more often in bladder carcinoma. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10942

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12436434     DOI: 10.1002/cncr.10942

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines.

Authors:  G Haramis; Z Zhou; A Pyriochou; M Koutsilieris; C Roussos; A Papapetropoulos
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

2.  CCAAT-binding factor regulates expression of the beta1 subunit of soluble guanylyl cyclase gene in the BE2 human neuroblastoma cell line.

Authors:  Iraida G Sharina; Emil Martin; Anthony Thomas; Karen L Uray; Ferid Murad
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

3.  Chronic inflammation in urothelial bladder cancer.

Authors:  Gabriella Nesi; Stefania Nobili; Tommaso Cai; Saverio Caini; Raffaella Santi
Journal:  Virchows Arch       Date:  2015-08-12       Impact factor: 4.064

Review 4.  Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer.

Authors:  Zhaowei Zhu; Zhoujun Shen; Chen Xu
Journal:  Mediators Inflamm       Date:  2012-07-02       Impact factor: 4.711

Review 5.  The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment.

Authors:  Francesco De Sanctis; Sara Sandri; Giovanna Ferrarini; Irene Pagliarello; Silvia Sartoris; Stefano Ugel; Ilaria Marigo; Barbara Molon; Vincenzo Bronte
Journal:  Front Immunol       Date:  2014-02-24       Impact factor: 7.561

6.  Increased H2S and its synthases in urothelial cell carcinoma of the bladder, and enhanced cisplatin-induced apoptosis following H2S inhibition in EJ cells.

Authors:  Wasilijiang Wahafu; Junwei Gai; Liming Song; Hao Ping; Mingshuai Wang; Feiya Yang; Yinong Niu; Nianzeng Xing
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

7.  Loss of NOS1 expression in high-grade renal cell carcinoma associated with a shift of NO signalling.

Authors:  K Renaudin; M G Denis; G Karam; G Vallette; F Buzelin; C L Laboisse; A Jarry
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.